ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) vs placebo
Leaving the study early · 18 to 85 year‐old patients with schizophrenia, schizoaffective disorder, mood disorder, or gastrointestinal disorder +…
It is very uncertain whether ENZYME INHIBITOR ‐ VMAT2‐INHIBITOR (valbenazine) changes leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
- Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyRR 1 [0.31, 3.25]1 study · 102 participantsVery low